Alpine Immune up on collaboration with Merck for cancer treatment study

Alpine Immune Sciences

30/06/2021 13:49

** Shares of drug developer  ALPN.O  rise 8.4% to $9.85
premarket
    ** Co enters clinical trial collaboration with Merck & Co
 MRK.N  to test its drug candidate ALPN-202 in combination with
MRK's immunotherapy Keytruda in patients with advanced
malignancies  urn:newsml:reuters.com:*:nBw5vtkdNa
    ** Says the clinical trial began dosing study participants
in June 
    ** ALPN had fallen 27.9% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))